In patients with mild to moderate malnutrition receiving ENEFLUID® as IDPN for 12 weeks during maintenance hemodialysis, serum TTR, a mortality predictor for patients on hemodialysis, was not increased; however, decrease in protein intake was mitigated, and no adverse events were observed. This evidence concerns the gene TTR and nutritional deficiency disease.